Rules-Based Medicine, Inc. (RBM), today announced the widespread commercial availability of VeriPsych™, the first and only blood-based diagnostic test to aid in confirming the diagnosis of recent onset schizophrenia, a potentially devastating and costly mental illness that affects about 24 million people worldwide. VeriPsych is an innovative molecular diagnostic tool designed to complement the healthcare provider’s clinical impression.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/rulesbasedmedicine/46237/
As part of their ongoing partnership to help Americans improve their health and curb the onset of chronic diseases like diabetes, CVS/pharmacy and the 50 Million Pound Challenge announced today the availability of the 32-page 50 Million Pound Challenge Guide in all CVS/pharmacy retail locations.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/43523/
On the eve of his 16th birthday, Greyson McCluskey from Indian Trail, North Carolina was named the national winner of Wouldn’t It Be Cool If…, a campaign jointly presented by Time Warner Cable’s philanthropic science, technology, engineering and math (STEM) initiative, Connect a Million Minds, and i.am FIRST, founded by artist, entertainer and entrepreneur will.i.am. The campaign challenged youth ages 10 – 15 to dream up the coolest idea to make their life, community or the world more awesome, and then to think about how science and math could help bring those ideas to life. Greyson McCluskey, an honor student and aspiring architect, developed his Baby Safe Rider – a mechanism for toddler car seats that would detect the onset of heightened temperatures in babies – as a way to address the rising incidents of vehicular Hyperthermia fatalities in the U.S. Greyson was inspired to create the Baby Safe Rider after the recent birth of his cousin. He entered the Wouldn’t It Be Cool If… contest after his mom saw a national public service announcement featuring will.i.am.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55955-time-warner-will-i-am-first-connect-a-million-minds-wouldnt-it-be-cool-if
Today the International OCD Foundation (IOCDF), announced their support for children and families suffering from Sudden Onset Obsessive Compulsive Disorder. They are releasing two new PSAs created to bring awareness and engender change surrounding the disorder PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) and PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome).
To view Multimedia News Release, go to http://www.multivu.com/mnr/54781-ocd-foundation-pandas-psa-obsessive-compulsive-disorder
In a revolutionary treatment for early-onset scoliosis (EOS), a team of surgeons implanted adjustable growing rods in two children from California. The pioneering surgeries — the first ever in the United States — were performed on May 7th at Rady Children’s Hospital in San Diego. The Food and Drug Administration (FDA) granted Compassionate Use approval to use the MAGEC™ (MAGnetic Expansion Control) System, developed by Ellipse Technologies, Inc., for these two patients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61604-rady-children-s-hospital-san-diego-ellipse-magec-early-onset-scoliosis-eos
A teenage piano prodigy enlists the help of renowned pianist Clare Cardiff. Though she is more than twice his age, he falls in love with her. After Clare is diagnosed with early onset dementia, she is taken away to pursue further medial testing. Clive is faced with the challenge of traveling to Moscow and performing at the competition without his beloved mentor. Find out more at – http://MargaretPhilbrick.com Literary Fiction/Romance
Persistent deterioration of short-term memory, progressive confusion and disorientation and frequent agitation are characteristic of Alzheimer’s disease. We have been told that it is largely genetic but that there are some things that can be done to reduce the severity or how early the onset is. We can’t change our genetic makeup but we can change our behavior to help mitigate the effects of this type of dementia. These are all things we can accomplish with a little determination and planning. http://youtu.be/9eMrmVMuAa0
Cision, a leading global media intelligence and communications solution provider and portfolio company of GTCR, announced that Kevin Akeroyd has been named global chief executive officer (CEO), effective today. Akeroyd succeeds Peter Granat, who established the company’s position as a global public relations and marketing cloud leader, and will transition to chairman of the Cision Board of Directors.
Akeroyd has more than 25 years of experience in reshaping modern digital, social and mobile marketing globally. Most recently he was general manager and senior vice president at Oracle Marketing Cloud where he orchestrated and executed the industry’s most prolific acquisition strategy, including Marketing Automation, Omni-Channel Campaign Management, Web Personalization, Content Marketing, DMP, Mobile Marketing, Data, and X-Device Orchestration. Under Akeroyd’s leadership, Oracle went from a non-entity to the #2 player in the entire industry in under three years, growing the business in 29 countries globally, and boasting the highest organic growth rate of all the major Marketing Cloud providers rate three years running. Integrating the solutions and the go-to-market, Akeroyd and Oracle created the Enterprise Marketing Platform category and have led it from the onset.
To view the multimedia release go to:
http://www.multivu.com/players/English/7896951-cision-kevin-akeroyd-new-global-ceo/
With the onset of winter season in the country, breathing problems and respiratory diseases will also be on the rise. To ensure that patients with respiratory problems breathe with ease, a comprehensive patient Mobile App named “My Breathefree” has been launched as a virtual caregiver by ‘Breathefree’, a public service initiative by Cipla. This app is specifically designed for Indian conditions and is available on Google play store and iOS platform for all patients, caregivers and doctors.
One of the major chronic respiratory problems in the country is asthma and “My Breathefree” app will be a great help towards better asthma management and control. Asthma causes limitations in daily activities, loss of school and work days, lung function impairment, reduced quality of life and an adverse socioeconomic burden. However, if monitored and treated properly, asthmatics can control their disease and lead an absolutely normal and healthy life.
To view the multimedia release go to:
http://www.multivu.com/players/English/7562351-lung-care-asthma-mobile-app/
Soy consumption is up 14 percent since 2011,26 yet confusion lingers over soy’s role in everything from human health to food production. To clear up misperceptions, the United Soybean Board (USB) busts five common soy myths with science-backed facts on SoyConnection.com/soy-wisdom.
1) Eating soy does not increase breast cancer risk.
Clinical studies show soy isoflavone exposure does not adversely affect breast tissue as assessed by markers of breast cancer risk, such as breast cell proliferation.1–7 The American Institute for Cancer Research and the American Cancer Society say that women who have been diagnosed with breast cancer can safely consume soyfoods. In fact, the World Cancer Research Fund International has identified a link between soy consumption and an improved survival of breast cancer patients.8-9
“Not only does evidence indicate soyfoods may benefit women with breast cancer, but consuming soy when young helps prevent the onset of this disease later in life27-30,” stated Mark Messina, Ph.D., who has dedicated the past 30 years to understanding the health effects of soyfoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7877951-united-soybean-board-top-soy-myths/
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
